201 related articles for article (PubMed ID: 18991497)
1. Growth inhibition and chemosensitization of exogenous nitric oxide released from NONOates in glioma cells in vitro.
Weyerbrock A; Baumer B; Papazoglou A
J Neurosurg; 2009 Jan; 110(1):128-36. PubMed ID: 18991497
[TBL] [Abstract][Full Text] [Related]
2. Selective opening of the blood-tumor barrier by a nitric oxide donor and long-term survival in rats with C6 gliomas.
Weyerbrock A; Walbridge S; Pluta RM; Saavedra JE; Keefer LK; Oldfield EH
J Neurosurg; 2003 Oct; 99(4):728-37. PubMed ID: 14567609
[TBL] [Abstract][Full Text] [Related]
3. Nitric oxide donors attenuate clongenic potential in rat C6 glioma cells treated with alkylating chemotherapeutic agents.
Yang JJ; Yin JH; Yang DI
Neurosci Lett; 2007 May; 418(1):106-10. PubMed ID: 17412510
[TBL] [Abstract][Full Text] [Related]
4. Growth-inhibitory and chemosensitizing effects of the glutathione-S-transferase-π-activated nitric oxide donor PABA/NO in malignant gliomas.
Kogias E; Osterberg N; Baumer B; Psarras N; Koentges C; Papazoglou A; Saavedra JE; Keefer LK; Weyerbrock A
Int J Cancer; 2012 Mar; 130(5):1184-94. PubMed ID: 21455987
[TBL] [Abstract][Full Text] [Related]
5. Targeted diazeniumdiolates: localized nitric oxide release from glioma-specific peptides and proteins.
Safdar S; Taite LJ
Int J Pharm; 2012 Jan; 422(1-2):264-70. PubMed ID: 22101282
[TBL] [Abstract][Full Text] [Related]
6. JS-K, a glutathione S-transferase-activated nitric oxide donor with antineoplastic activity in malignant gliomas.
Weyerbrock A; Osterberg N; Psarras N; Baumer B; Kogias E; Werres A; Bette S; Saavedra JE; Keefer LK; Papazoglou A
Neurosurgery; 2012 Feb; 70(2):497-510; discussion 510. PubMed ID: 21849924
[TBL] [Abstract][Full Text] [Related]
7. Proteomic analysis of human glioblastoma cell lines differently resistant to a nitric oxide releasing agent.
Leone R; Giussani P; De Palma S; Fania C; Capitanio D; Vasso M; Brioschi L; Riboni L; Viani P; Gelfi C
Mol Biosyst; 2015 Jun; 11(6):1612-21. PubMed ID: 25797839
[TBL] [Abstract][Full Text] [Related]
8. A glycosylated nitric oxide donor, beta-Gal-NONOate, and its site-specific antitumor activity.
Chen C; Shi Y; Li S; Qi Q; Gu L; Song J; Wang PG
Arch Pharm (Weinheim); 2006 Jul; 339(7):366-71. PubMed ID: 16783837
[TBL] [Abstract][Full Text] [Related]
9. Effects of the nitric oxide donor JS-K on the blood-tumor barrier and on orthotopic U87 rat gliomas assessed by MRI.
Weidensteiner C; Reichardt W; Shami PJ; Saavedra JE; Keefer LK; Baumer B; Werres A; Jasinski R; Osterberg N; Weyerbrock A
Nitric Oxide; 2013 Apr; 30():17-25. PubMed ID: 23370169
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and biological effects of NO in malignant glioma cells: modulation by cytokines including CD95L and TGF-beta, dexamethasone, and p53 gene transfer.
Rieger J; Ständer M; Löschmann PA; Heneka M; Dichgans J; Klockgether T; Weller M
Oncogene; 1998 Nov; 17(18):2323-32. PubMed ID: 9811463
[TBL] [Abstract][Full Text] [Related]
11. Increase in brain tumor permeability in glioma-bearing rats with nitric oxide donors.
Yin D; Wang X; Konda BM; Ong JM; Hu J; Sacapano MR; Ko MK; Espinoza AJ; Irvin DK; Shu Y; Black KL
Clin Cancer Res; 2008 Jun; 14(12):4002-9. PubMed ID: 18559623
[TBL] [Abstract][Full Text] [Related]
12. Prolonged survival of mice with established intracerebral glioma receiving combined treatment with peroxisome proliferator-activated receptor-gamma thiazolidinedione agonists and interleukin-2-secreting syngeneic/allogeneic fibroblasts.
Spagnolo A; Glick RP; Lin H; Cohen EP; Feinstein DL; Lichtor T
J Neurosurg; 2007 Feb; 106(2):299-305. PubMed ID: 17410715
[TBL] [Abstract][Full Text] [Related]
13. Coadministration of sorafenib with rottlerin potently inhibits cell proliferation and migration in human malignant glioma cells.
Jane EP; Premkumar DR; Pollack IF
J Pharmacol Exp Ther; 2006 Dec; 319(3):1070-80. PubMed ID: 16959960
[TBL] [Abstract][Full Text] [Related]
14. Differential effects of PPARgamma agonists on the metabolic properties of gliomas and astrocytes.
Spagnolo A; Grant EN; Glick R; Lichtor T; Feinstein DL
Neurosci Lett; 2007 Apr; 417(1):72-7. PubMed ID: 17324516
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of cell growth and proliferation in human glioma cells and normal human astrocytes induced by 8-Cl-cAMP and tiazofurin.
Pesic M; Drabek K; Esler C; Ruzdijic S; Pejanovic V; Pietrzkowski Z
Nucleosides Nucleotides Nucleic Acids; 2000; 19(5-6):963-75. PubMed ID: 10893715
[TBL] [Abstract][Full Text] [Related]
16. Selective cytotoxicity of indomethacin and indomethacin ethyl ester-loaded nanocapsules against glioma cell lines: an in vitro study.
Bernardi A; Frozza RL; Jäger E; Figueiró F; Bavaresco L; Salbego C; Pohlmann AR; Guterres SS; Battastini AM
Eur J Pharmacol; 2008 May; 586(1-3):24-34. PubMed ID: 18371953
[TBL] [Abstract][Full Text] [Related]
17. Differential effects of nitric oxide on blood-brain barrier integrity and cerebral blood flow in intracerebral C6 gliomas.
Weyerbrock A; Walbridge S; Saavedra JE; Keefer LK; Oldfield EH
Neuro Oncol; 2011 Feb; 13(2):203-11. PubMed ID: 21041233
[TBL] [Abstract][Full Text] [Related]
18. Targeting autophagy enhances BO-1051-induced apoptosis in human malignant glioma cells.
Chu PM; Chen LH; Chen MT; Ma HI; Su TL; Hsieh PC; Chien CS; Jiang BH; Chen YC; Lin YH; Shih YH; Tu PH; Chiou SH
Cancer Chemother Pharmacol; 2012 Mar; 69(3):621-33. PubMed ID: 21947203
[TBL] [Abstract][Full Text] [Related]
19. Growth inhibition and radiosensitization of cultured glioma cells by nitric oxide generating agents.
Kurimoto M; Endo S; Hirashima Y; Hamada H; Ogiichi T; Takaku A
J Neurooncol; 1999 Mar; 42(1):35-44. PubMed ID: 10360477
[TBL] [Abstract][Full Text] [Related]
20. Role of redox signaling and poly (adenosine diphosphate-ribose) polymerase activation in vascular smooth muscle cell growth inhibition by nitric oxide and peroxynitrite.
Huang J; Lin SC; Nadershahi A; Watts SW; Sarkar R
J Vasc Surg; 2008 Mar; 47(3):599-607. PubMed ID: 18295111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
